Pilot Results from Application of Muses Labs’ Technology-Enabled, Multi-Modal Protocol for Alzheimer’s Disease are Encouraging and Suggest Further Study
RALEIGH, N.C. (Business Wire) July 20, 2016 – Muses Labs announced today it will showcase its technology and services at booth #108 at the Alzheimer’s Association International Conference (AAIC) 2016 in Toronto, Canada, July 24-28, 2016. In addition, John Q. Walker, Ph.D., Muses Labs’ chief technology officer, will present results of pilot work from the application of the company’s first personalized protocol targeted to age-related cognitive decline.
Muses Labs’ Protocol is a data-driven, technology-enabled personalized methodology to correctly identify and simultaneously treat the dozens of pathology drivers of age-related cognitive decline. It is designed to help people who are beginning to have symptoms of age-related cognitive decline, those with a family history of dementia and those with mild Alzheimer’s disease. Proprietary algorithms within the Protocol recommend optimal medical interventions personalized for each person with a goal of improving memory and cognitive function.
Muses Labs has applied its Protocol to more than 125 self-selected people with cognitive decline in a pilot effort. Each person’s genome, blood tests, medical history and lifestyle were processed by Muses Labs’ proprietary technology. These individuals then worked with their physicians to follow their personalized multi-modal protocols. Of those who completed at least two cycles of protocols over the course of three or more months, more than 50 percent improved their cognitive function as measured by industry-standard neuropsych tests. Almost all of those identified as “early-symptomatic” observed improved memory function and improvement in key biomarkers.
Dr. Walker will present details of these pilot findings during Session IV of the AAIC Technology and Dementia Preconference. His presentation, “Initial Development, Application and Results from a Clinical Informatics Platform that Enables a Multi-Modal Treatment Protocol for Alzheimer’s Disease,” will be held Saturday, July 23 from 3:10 to 3:30 p.m. Dr. Walker will also present a poster on clinical therapeutics Monday, July 25 from 9:30 a.m. to 10:30 a.m.
“A multi-modal combination approach has the potential to improve cognitive function for early-symptomatic individuals,” Dr. Walker said. “Currently available interventions used in personalized combinations let individuals with age-related cognitive decline have the potential to continue their independent and active lifestyles. Our continuing work with larger populations will further refine our methodology and build a larger base of quantified patient outcomes. Larger randomized studies of multi-modal approaches are warranted.”
The Technology and Dementia track convenes researchers using technological-based research, including mobile technology, home-based technology and social networking, to apply innovative study design and potential solutions to Alzheimer’s disease and related dementia research. The program targets researchers invested in the development and validation of technological resources for individuals affected by dementia.
AAIC is the world’s largest forum for the dementia research community. International investigators, clinicians and care providers gather annually to share the latest study results, theories and discoveries that bring the world closer to breakthroughs in dementia science. As a part of the association’s research program, AAIC serves as a catalyst for generating new knowledge about Alzheimer’s and fostering a vital and collegial research community.
Contact us to schedule a time to meet with a Muses Labs team member at AAIC 2016 to learn more about the MEND Protocol and recent study results. For additional information, please call 984.232.6699 or visit www.museslabs.com.
About Muses Labs
Muses Labs brings together 30 years of scientific research, hundreds of published clinical studies, and a team of highly respected Alzheimer’s researchers, doctors and advanced technology. The company applies its clinical precision medicine platform and technology-enabled protocol to collect individual patient medical and behavioral data, identify underlying causes of age-related cognitive decline (such as Alzheimer’s disease and memory loss) and design personalized treatment plans. A comprehensive adherence program supports individuals and their caregivers to improve patient outcomes. This first personalized protocol is called the MENDTM Protocol (Metabolic Enhancement for NeuroDegeneration). For more information, visit www.museslabs.com.
Crossroads Public Relations and Marketing
Molly Thompson, Account Director